ZAKA VC
VC Fund
Prague, Czech Republic
ZAKA VC is a VC fund in Prague focused on Artificial Intelligence and Software. ZAKA Startups is a private pre-seed and seed venture capital company. It is focused on early-stage software driven investments across the whole EU with primary focus on CEE, DACH and Baltics. ZAKA operates primarily from Prague and Bratislava with scouts in Berlin and Baltic region.
- Total investments:
- 110
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries ZAKA VC invests in
Stages ZAKA VC invests in
Countries ZAKA VC invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $520k–$7M
- Pre-Seed
- $250k–$1M
Investment Focus
Industry
- Artificial Intelligence 11 (10%)
- Software 10 (9%)
- Information Technology 7 (6%)
- Biotechnology 6 (5%)
- Machine Learning 5 (5%)
Stage
- Seed 26 (24%)
- Pre-Seed 8 (7%)
- Funding Round 8 (7%)
- Series A 3 (3%)
Country
- United States 12 (11%)
- Germany 4 (4%)
- United Kingdom 4 (4%)
- Austria 3 (3%)
- Estonia 3 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrej Petrus
Chief investment officer
|
Chief investment officer | Total investments: 5 | Find email | |
Jan Kasper
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 12 | Find email | |
Marian Mudry
Advisor
|
Advisor | Total investments: 0 | Find email | |
Samuel Zalesak
Junior Analyst & Member of Supervisory Board
|
Junior Analyst & Member of Supervisory Board | Total investments: 1 | Find email | |
Slavo Tuleya
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Human Archive
|
Human Archive builds human data archiving platform with comprehensive dataset for training embodied AI and robotics systems. | $8.2M / Seed / May 26, 2026 | |
ParcelBio
|
ParcelBio is a company that creating a programmable method for safely and precisely delivering mRNA to many cell types in the body. | $13M / Seed / May 07, 2026 | |
Ateios
|
Ateios is enabling a new generation of thin and flexible electronics with our ultra-thin, conformable, and customizable batteries. The company's current focus is zinc-oxide batteries, that achieve 2-5x higher energy density compared to coin cells. Ateios’ novel manufacturing process allows customizable batteries that can be shaped around theneeds of the product.The company was founded in 2018. | $7.3M / Series A / Mar 23, 2026 | |
Cell Type
|
Cell Type develops models that simulate human drug response and analyze single-cell data for target selection and clinical design. | $500K / Pre-Seed / Mar 01, 2026 | |
Readmio
|
Readmio is an app full of stories and tales for children. As a parent reads a story out loud to their child, the app uses voice recognition technology to add fitting sounds, for even more fun. Readmio was launched in June 2020 and offers 200+ stories in English, Czech, and Slovak. It has been downloaded by more than 140,000 people who have read totheir children, grandchildren, or siblings almost a million times. On average, that's more than 80,000 hours that people have spent together reading, smiling, learning, being together. And that's what Readmio is set to achieve - help parents spend more quality time with their children, reading engaging stories that support mental development, foster imagination, and instill humanity. | $1.2M / Seed / Feb 05, 2026 | |
DeepSeq.AI
|
DeepSeq.AI was founded in 2019, with the overall mission of decoding the relationship between protein sequences and functions by combining wet-lab, software, and AI in a continuous development loop in order to design and screen novel protein drugs more efficiently. Up to date, DeepSeq.AI has developed a unique next-generation sequencing (NGS) basedAI platform to help pharma companies design novel protein drugs with high speed and accuracy.In 2021, DeepSeq.AI started to work with one of the top-10 global biopharma on feasibility studies to accelerate their drug discovery efforts. Those collaborations were successful, and we presented one of our successful projects at the Protein Engineering Summit Boston (PEGS) in May 2023, along with a number of other top biopharma and technology companies (e.g., Pfizer, Amgen, IBM). In Nov 2023, DeepSeq.AI was funded by UC Berkeley SkyDeck Fund and Merck Digital Sciences Studio (MDSS). | Venture - Series Unknown / Jan 07, 2026 | |
VETSTOR
|
VETSTOR is an online platform that connects with veterinarians and pet owners to recommend and sell quality foods and medications. | $1.2M / Seed / Dec 09, 2025 | |
Zephyr Fusion
|
Zephyr Fusion builds fusion powered satellite technologies that enable megawatt scale energy and aerospace operations in orbit. | $500K / Pre-Seed / Dec 03, 2025 | |
LunaBill
|
LunaBill builds billing automation software with AI Voice Agents to handle insurance calls for healthcare billing teams. | $500K / Pre-Seed / Nov 11, 2025 | |
Kano Therapeutics
|
Kano Therapeutics focuses on the correction of gene-length DNA using circular single-stranded DNA biomaterials. The company provides a comprehensive platform that combines manufacturing, application, and computational tools for genetic payload development. This approach empowers researchers and organizations to advance genetic cures effectively andsafely. | Seed / Nov 07, 2025 | |
| See all 110 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does ZAKA VC invest in?
ZAKA VC invests primarily in Artificial Intelligence, Software and Information Technology startups, most often at Seed and Pre-Seed stage. Most of the 110 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is ZAKA VC's check size?
ZAKA VC typically joins rounds of $520k–$7M at Seed and $250k–$1M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ZAKA VC participates in.
How do I contact ZAKA VC?
Public channels for ZAKA VC include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ZAKA VC?
The team at ZAKA VC includes Andrej Petrus (Chief investment officer), Jan Kasper (Co-Founder & Managing Partner) and Marian Mudry (Advisor). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
